natgillin/translations-raw huggingface dataset:
A drug delivery device suitable for providing local analgesia, local anesthesia or nerve blockade at a site in a human or animal in need thereof, the device comprising a fibrillar collagen matrix; and at least one drug substance, the at least one drug substance being substantially homogeneously dispersed in the collagen matrix, and the at least one drug substance being present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least one day after administration wherein the drug delivery device comprises a plurality of collagen sponges, each collagen sponge having 3.6 to 8mg/cm3 type I collagen, and 2.0 to 6.0mg/cm3 bupivacaine hydrochloride. 
HR P20190699 T1 PATENTNI ZAHTJEVI Naprava za dopremu lijeka pogodna za omogućavanje lokalne analgezije, lokalne anestezije ili blokade živca na određenom mjestu kod potrebitog čovjeka ili životinje, naprava obuhvaća matricu od fibrilarnog kolagena; i barem jednu ljekovitu tvar, najmanje jedna ljekovita tvar je sadržajno homogeno raspršena u matrici kolagena, pri čemu naprava za dopremu lijeka sadrži jednu ili nekoliko liofiliziranih kolagen spužvi koje ukupno sadrže 250 mg ili 200 mg anhidridnog bupivakain hidroklorida.
The composition of claim 8, wherein the methyl paraben, propyl paraben, or a combination thereof is present in a concentration of about 0.18% w/v and about 0.02% w/v, respectively. 
Sastav prema zahtjevu $, gdje se metil paraben i/ili propil paraben koriste u koncentraciji od oko 0,18 % wfv, odnosno oko 0,02 % w/v.
wherein R2, R4, R8 and R9 are as defined in Table 1 above, P3 is a NH protecting group such as carbobenzyloxy (CBZ), and R11 and R12 are as defined in Table 1 above for R8 and R9, respectively. 
HR P20080057 T3 gdje R», Ra, Rg 1 Ro su kao što je definirano u tabeli 1 gore, P; je NH zaštitna skupina kao npr. karbobenziloksi (CBZ), i R;:1 Rio su kao što je definirano u tabeli 1 gore za Rg odnosno Ra.
thionyl chloride (SOCl2) was slowly charged to the flask. 
tionil klorida HR P20080057 T3 (SOCL) je bilo polagano stavljeno u tikvicu.
The combination of any one of claims 1 to 5 of structural formula Ic having the indicated absolute stereochemical configuration at the three stereogenic carbon atoms marked with an *: 
Spoj prema patentnom zahtjevu 11 strukturne formule Ic koji ima naznačenu apsolutnu stereokemijsku konfiguraciju na tri stereogena atoma ugljika označena sa *: [image]
The radioactive metal-labeled anti-P-cadherin antibody according to any one of claims 1 to 3, wherein the mole ratio of the anti-P-cadherin antibody to the metal-chelating reagent is 1: 0.1 to 1: 4.5, preferably 1: 0.5 to 1: 3. 
Anti-P-kadherin antitijelo obilježeno radioaktivnim metalima u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačeno time, da je molni omjer anti-P-kadherin antitijela u odnosu na reagens za keliranje metala od 1: 0,1 do 1: 4,5, poželjno 1: 0,5 do 1: 3.
In the most preferred embodiment of the method of treatment or vaccine according to the invention, the vaccine is a multiple peptide tumor vaccine for treatment of GBM. 
Peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 4 za uporabu u liječenju karcinoma ili za uporabu u proizvodnji cjepiva protiv karcinoma.
an input shaft (19) and an output shaft (2) rotatable about respective axes (18,3); 
- < ulazno vratilo (19) i izlazno vratilo (2), koji se mogu zakretati oko svojih osi (18, 3);
Compounds of formula (I) wherein the link between C7 and C8 in the macrocycle is a single bond, i.e. compounds of formula (I-j), can be prepared from the compounds of formula (I-i) by a reduction of the C7-C8 double bond in the compounds of formula (I-i). 
' > (b) pretvorbe spoja formule (I-i) u spoj formule (1) pri čemu veza između C7 i Cg u makrociklu je jednostruka veza, na primjer spoj formule (I-j): oF
The bone plate system of claim 1, wherein the plurality of discrete columns (1142) of protrusions are spaced equidistantly apart around the inner surface (1135) of the hole (1140). 
Sustav u skladu s patentnim zahtjevom 1, naznačen time, da navoj profila ima profilne linije (618) koje se sijeku u centru (626) polumjera zakrivljenosti lučnog segmenta (625).
Advantageously, the pressure lowering agent selected from ACE-inhibitors to be used in the composition of the present invention is selected from the group consisting of captopril, enalapril, lisinopril, ramipril, and perindopril. 
Farmaceutski sastav prema zahtjevu 1, naznačen time, da je navedeni ACE-inhibitor odabran iz skupine koju čine kaptopril, enalapril, lizinopril, ramipril 1 perindopril.
the residual little a.i. containing plant components are separated from the a.i. containing solvent, against plant pathogenic fungi, in particular against downy mildews of crops, wherein the plant pathogenic fungi is belonging to the family phyla Oomycota. 
(d) ostatak biljnih dijelova koji sadrže malu količinu djelatnog sastojka, odvaja se od otapala koje obuhvaća djelatni sastojak, pri čemu se ekstrakt upotrebljava protiv biljnih patogenih gljivica, posebice protiv pahuljaste snijeti (peronospore) kod biljnih usjeva, dok biljne patogene gljivice pripadaju u porodicu phyla Oomycota.
The resulting solid is re-crystallized from ethyl acetate/iso-hexane to yield the titled product as a white solid. 
Dobivenu krutu tvar se prekristalizira iz etil acetat/izo-heksana, čime se dobije naslovni proizvod kao bijela kruta tvar.
A typical dry solid pharmaceutical composition is prepared by blending the following materials together in the proportions by weight specified below: After the dried composition is thoroughly blended, tablets are punched from the resulting mixture, each tablet being of such size that it contains 100 mg. of the active ingredient. 
Magnezij-stearat 5 Nakon što se osušeni preparat potpuno pomiješa, tablete se štancaju iz nastale smjese, pri čemu je svaka tableta takve veličine da sadrži 100 mg aktivnog sastojka.
A combination according to claim 1 wherein R1 is selected from H, -COR8, or alkyl. 
Sastav prema zahtjevu 1 naznačen time da R, je odabran od H, -COR, ili alkila.
One embodiment of the present invention may comprise a surface relief on an inner or outer surface of the packaging. 
Jedno ostvarenje predmetnog izuma može sadržavati plošni reljef na unutarnjoj ili na vanjskoj površini pakiranja.
2 or a homologue thereof having an amino acid identity of at least 95%, which homologue contains valine as amino acid in position 239 or the position corresponding thereto.. 
2 ili njezin homolog koji ima identičnost amino kiseline od barem 95%, koji homolog sadrži valin kao amino kiselinu na položaju 239 ili na položaju koji mu odgovara.
Other assay techniques include (but are not limited to) measurement of the effects of GnRH receptor antagonists on the inhibition of GnRH-stimulated calcium flux, modulation of phosphoinositol hydrolysis, and the circulating concentrations of gonadotropins in the castrate animal. 
Drugc tehnike ispitivanja uključuju (no nc ograničuju sc na) mjerenje učinaka antagonista receptora GnRH na inhibiranje GnRH-om stimuliranog protoka kalcija, moduliranje hidrolize fosfoinozitola, te u koncentracijama gonadotropina u krvotoku kod kastrirane životinje.
The formulation for use according to claim 6 wherein the composition or product is formulated for intradermal administration, oral administration, nasal administration, subcutaneous administration, sublingual administration or for administration by inhalation or by injection. 
Formulacija za uporabu u skladu sa zahtjevom 10, naznačena time, što je sastav, vektor ili proizvod formuliran za intradermalnu primjenu, oralnu primjenu, nosnu primjenu, potkožnu primjenu, sublingvalnu primjenu ili za primjenu udisanjem ili injektiranjem.
The bone plate system of claim 1, wherein the plurality of discrete columns (1142) of teeth or thread segments are spaced equidistantly apart around the inner surface (1135) of the hole (1140). 
Sustav u skladu s patentnim zahtjevom 1, naznačen time, da navoj profila ima profilne linije (618) koje se sijeku u centru (626) polumjera zakrivljenosti lučnog segmenta (625).
After this time, the solution was concentrated under reduced pressure to give the title compound, 2-(chloromethyl)-5-(trifluoromethyl)pyridine HCl salt. 
Nakon ovog vremena otopina je koncentrirana pod smanjenim tlakom pri čemu se dobiva spoja iz naslova, 2-(klorometil)-5-(trifluorometil)piridin HC1 sol.
Ulipristal acetate, or any metabolite selected from the group consisting of CDB-3877, CDB-3963, CDB-3236, and CDB-4183, for use in reducing or stopping bleedings in a patient suffering from uterine fibroids according to any one of claims 1-3 wherein it is to be administered with a daily dosage of 5 to 15 mg . 
Ulipristal acetat, 1li bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB- 4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema bilo kojem od zahtjeva 1-3 pri čemu se primjenjuje u dnevnoj dozi od 5 do 15 mg.
The results of the tests are shown in Tables 5 to 9. 
Rezultati ovih testova su prikazani u Tabelama 5 do 9.
The optical element (OP) according to claim 1, wherein the reflector (12, 13) is constructed to reflect sunlight under an angle within a range of 20 to 70, preferably 30 to 60 and most preferably 40 to 55 degrees with respect to the optical axis of the optical element. 
Informacijski sustav u skladu sa patentnim zahtjevom 1, gdje je reflektor (12, 13) konstruiran da reflektira sunčevu svjetlost pod kutom, u opsegu od 20 do 70, poželjno 30 do 60 1 najpoželjnije 40 do 55 stupnjeva u odnosu na optičku os od optičkog elementa do prigušivača (10).
The compound, tautomer or pharmaceutically acceptable salt thereof for use, according to claim 7 wherein the disease or disorder is spondyloarthritis. 
Spoj, njegov tautomer ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 7, naznačen time što je bolest 1li poremećaj spondiloartritis.
The aqueous wash was extracted with dichloromethane and the combined organic layers were extracted with 5M HCl (2x12.5 ml). 
Vodeni ispirak ekstrahira se diklormetanom, a pomiješane organske slojeve ekstrahira s 5 M HCI (2 x 12,5 ml).
reacting said compound of formula (III) with a cyanide salt to obtain the corresponding nitrile compound of formula (IV). 
F (III) 1i) pretvorba spoja formule (III) u odgovarajući nitrilni derivat formule (TV).
Preferably, the (CH2CH2O)n moiety has a weight-average molecular weight of about 20 kD or 30 kD. The conjugate in which -SR is the polypeptide (E10C)hPYY3-36 is of particular interest. 
Konjugat u skladu s patentnim zahtjevom 6 ili patentnim zahtjevom 9, gdje ostatak (OCH2CH.), ima prosječnu molekulsku težinu od otprilike 30 kD. 11.
A method according to Claim 8, wherein the veil is substantially pervious to a component of the moulding material during the moulding. A method according to any preceding claim, wherein a further layer of sheet-form moulding material is applied to an opposing surface of the substrate, the application of pressure sandwiching the substrate between the two layers of sheet-form material. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time, da se nanosi dodatni sloj pločastog materijala za oblikovanje u kalupu na suprotnu površinu nosivog materijala, gdje se primjenom tlaka, nosivi materijal steže u sendvič konstrukciju između dva sloja pločastog materijala.
a heteroaryl group selected from unsubstituted pyrrole, thiophene, furane, indole, imidazole, thiazole, oxazole, pyridine and pyrimidine; 
heteroarilna skupina je odabrana između nesupstituiranog pirola, tiofena, furana, indola, imidazola, tiazola, oksazola, piridina i pirimidina;
An aqueous adjuvant composition according to claim 6 wherein the derivative of QuilA is QS21. 
Vodeni adjuvantni pripravak u skladu s patentnim zahtjevom 6, naznačen time što je derivat QuilA QS21.
It should be noted that the particular knitting by means of which the therapeutic hosiery item according to the invention is produced allows to provide the heel and/or toe regions of the hosiery item without necessarily resorting to knitting with actuation of the needle cylinder with an alternating rotary motion about its own axis. 
Treba napomenuti da posebno pletenje, pomoću kojeg se izrađuje terapeutsku čarapu prema izumu, omogućuje dobivanje područja pete i/ili nožnih prstiju čarape bez neophodnog prebacivanja na pletenje s pokretanjem cilindra s iglama na naizmjenično okretanje oko njegove vlastite osi.
Detailed description of the invention: 
Broj objave europskog patenta:
A compound according to claim 1 that is 9-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-methyl-2,3,4,5-tetrahydropyrido[2,3-f][1,4]oxazepine or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je 9-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]-2-metil-2,3,4,5-tetrahidropirido[2,3-f][1,4]oksazepin, ili njegova farmaceutski prihvatljiva sol.
A pharmaceutical composition for the treatment of HCV infection, comprising an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt or ester thereof and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da služi za liječenje ili prevenciju HCV-infekcije, te da sadrži učinkovitu količinu spoja prema jednom ili više od zahtjeva 1 do Il, ili njegove farmaceutski prihvatljive soli ili njegovog estera, kao 1 farmaceutski prihvatljiv nosač.
In a process of producing glatiramer acetate comprising the step of deprotecting the protected glatiramer acetate with a solution of hydrobromic acid in acetic acid, the improvement comprising: pretreating the solution of hydrobromic acid in acetic acid with a bromine scavenger prior to use of the solution for deprotecting the protected glatiramer acetate. 
Postupak za proizvodnju glatiramer acetata, naznačen time, da sadrži stupanj skidanja zaštite sa zaštićenog glatiramer acetata otopinom bromovodične kiseline u octenoj kiselini, pri čemu poboljšanje sadrži: prethodnu obradu otopine bromovodične kiseline u octenoj kiselini hvatačem broma prije primjene otopine za skidanje zaštite sa zaštićenog glatiramer acetata,
is phenyl or pyridinyl, which are optionally substituted by halogen, C1-4-alkyl or C1-4-alkoxy; 
je fenil ili piridinil, koji je prema potrebi supstituiran s halogenom, C1-4-alkilom ili C1-4-alkoksi;
The compound of claim 1, wherein the compound is a compound of formula (VII), or an enantiomer, diastereomer, tautomer, or pharmaceutically-acceptable salt or solvate thereof, wherein the symbols have the following meaning and are, for each occurrence, independently selected: 
Spoj izabran iz skupine koju čine: [image] i [image] . Spoj formule V, [image] ili njegova farmaceutski prikladna sol, gdje simboli imaju sljedeća značenja i, za svako pojavljivanje, se biraju nezavisno:
Composition according to claims 2 or 3, characterised in that the ibuprofen is selected from the group formed by (R,S)-ibuprofen and (S)-ibuprofen. 
Pripravak u skladu s patentnih zahtjeva 1 ili 2, naznačen time što ibuprofen se bira iz skupine koju čine (R,S)-ibuprofen i (S)-ibuprofen.
The engine of claim 1, wherein the ratio of volume in the expansion cylinder when the expansion piston is at the expansion piston's bottom dead center (BDC) position to the volume in the expansion cylinder when the expansion piston is at the expansion piston's top dead center (TDC) position is 40 to 1 or greater. 
. Postupak opisan patentnim zahtjevom 16, naznačen time što je utvrđeno je da je omjer volumena cilindara od DMT do GMT u barem jednom od cilindara, ekspanzijskom (104) ili kompresijskom (106), približno 40 prema 1 ili veći.
Thus, the lozenges of the invention exhibit improved stability in storage. 
Prema tome, tablete prema izumu pokazuju poboljšanu stabilnost prilikom čuvanja.
Fig. 3 shows a perspective view of a line according to Fig. 2 in the closed position. 
prikazuje perspektivni pogled na cijev u skladu sa slikom 2 u zatvorenom položaju. S1.
Composition for the use according to any one of claims 1 to 4, characterised in that the peptide or polypeptide comprises 7 to 30, preferably 7 to 20, more preferably 7 to 16, most preferably 8, amino acid residues. 
Sastav za uporabu prema bilo kojem od zahtjeva 1 do 4, naznačen time, da peptid ili polipeptid sadrži od 7 do 30, poželjno od 7 do 20, još bolje od 7 do 16, te najbolje 8 aminokiselinskih ostataka.
A lock and key system as defined in claim 5, wherein said recesses at said longitudinal edge portion of the key blade (152) comprise cuts oriented at different angles relative to a plane oriented perpendicularly to the key blade (152). 
Sustav ključa 1 brave kako je definirano u zahtjevu 5, naznačen time da navedena udubljenja na navedenom uzdužnom dijelu kraka ključa (152) sadrže zareze orijentirane pod različitim kutovima u odnosu na ravninu orijentiranu okomito na krak ključa (152).
obtaining a transport stream, TS, to which the PLP is mapped, 
"> HIBUS Dobivanje prijenosnog toka u koji se PLP konvertira
The composition for use according to any one of Claims 1 to 5, wherein the HIF-1a 4-prolyl hydroxylase inhibitor is tert -butyl 4-{[1-(4-chlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl]methyl}piperazine-1-carboxylate. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je jedan ili više spojeva terc-butil-4-{[1-(4-klorbenzil)-3-hidroksi-2-okso-1,2-dihidropiridin-4-il]metil}piperazin-1-karboksilat, ili farmaceutski prihvatljiva sol, koju se bira između hidrokloridne soli, hidrogensulfatne soli, sulfatne soli, p-toluensulfonatne soli, metansulfonatne soli i njihovih smjesa.
Example 17: Recrystallization to obtain orthorhombic form 
Primjer 17: Rekristalizacija da bi se dobio ortorombski oblik
A compound of formula I: 
Spoj formule I: zo
The device according to claim 9, wherein a part of the light quantity of the optical conductor of a fibre strand is branched off to each switching device with a beam splitter and is forwarded to the switching device. 
Uređaj u skladu s patentnim zahtjevom 7, naznačen time što se dio količine svjetlosti optičkog vodiča u niti vlakna grana uzvodno od svakog prekidačkog uređaja djeliteljem snopa i šalje u prekidački uređaj.
% to about 40% of xylitol, sorbitol or sorbitol solution, or maltitol solution; provided that the ratio of the amount of (sucrose or invert sucrose): (xylitol, sorbitol or sorbitol solution, or maltitol solution) is equal or greater than about 1:1; and a preservative system comprising about 0.010% to about 0.058% of propylparaben, sodium propylparaben or potassium propylparaben; 
0 % do otprilike 40 % ksilitola, sorbitola ili otopine sorbitola ili otopine maltitola; uz uvjet da odnos količina (saharoza ili invertna saharoza)/(ksilitol, sorbitol ili otopina sorbitola ili otopina maltitola) je jednak ili veći od otprilike 1:1; 1 sustav konzervansa, koji sadrži otprilike 0,010 % do otpriliko 0,058 % propilparabena, natrij-propilparabena ili kalij-propilparabena; otprilike 0,0005 % do otpriliko 0,0350 % butilparabena ili natrij-butilparabena.
The method of Claim 14, wherein said emulsifier is selected from the group consisting of a polysorbate, sucrose ester, stearoyl lactylate, mono/diglyceride, diacetyl tartaric ester of mono/di-glycerides, phospholipid, propylene glycol alginate, lipophilic modified starch, or mixture thereof. 
Postupak u skladu s patentnim zahtjevom 14, gdje navedeni emulgator se bira iz skupine koju čine polisorbat, saharozni ester, stearoil-laktilat, mono-/diglicerid, ester diacetilvinske kiseline s mono-/digliceridima, fosfolipid, propilen-glikol-alginat, lipofilno modificirani škrob, ili njihova smjesa.
An alternative embodiment of a toilet basket according to the present invention for solid or gelled preparations having a flushing water distributing element arranged below the inlet opening is shown in FIG. 
WC košarica prema zahtjevu 1, naznačena time da je element za distribuciju vode za ispiranje (8) smješten ispod ulaznih otvora (5a, 5b, 5c, 5d).
Optionally, the coating composition may also include one or more of the following: from about 0.05% to 0.1% by weight of an antimicrobial, such as triclosan and more preferably methylparaben, a fungicide from about 50 to 5000 parts per billion such as TBZ, SOPP, or Imalzalil, and a plasticizer such as glycerin or polysorbate from about 0.1% to 20% to the weight of polyvinylidene chloride copolymer in the water based emulsion. 
Izborno, oblagajuća kompozicija također može sadržavati jedan ili više od sljedećih: od 0.05% do %% antimikrobnih sredstava kao što je triklosan i poželjnije metilparaben, fungicid od 50 do 5000 dijelova na milijardu kao što je TBZ, SOPP ili Imalzalil, i plastifikator kao što je glicerin i polisorbat od 0.1% do 20% prema masi poliviniliden klorid kopolimera u emulziji na bazi vode.
wherein Y represents an alkyl group; and Het represents a pyridyl group of formula (Het1) or a thiazolyl group of formula (Het2); 
Na ev (A) pri čemu Y predstavlja skupinu alkil; i * Het predstavlja skupinu piridil s formulom (Het):
the Crystal Violet is approximately 80% pure or greater; and the antimicrobial agent is Proclin 300. 
Crystal Violet je približno 80% čista 1li više; i antimikrobno sredstvo je Proclin 300.
EPMATHMARKEREP where A1 is the rate of animals with thrombotic occlusion in the treatment group A1; A2 is the rate of animals with thrombotic occlusion in the treatment group A2; and B is the rate of animals with thrombotic occlusion in the control group 
Frakcijska inhibicija = [1 - (A,/B x A2/B)] x 100 gdje A, je broj životinja s tromboznom okluzijom u liječenoj skupini A;; A2 je broj životinja s tromboznom okluzijom u liječenoj skupini A;; i B je broj životinja s tromboznom okluzijom u kontroloj skupini.
The taper of the container 1100 creates a dome-like structure that facilitates the blending of the contents of the container 1100 . 
Suženje posude 1100 čini oblik kupole koji olakšava miješanje sadržaja u posudi 1100.
The pharmaceutical composition according to Embodiment 1, wherein the S-ketamine hydrochloride is present in a concentration in the range of eq. 
Farmaceutski sastav prema zahtjevu 1, pri čemu S-ketamin hidroklorid se nalazi u koncentraciji u opsegu od ekv.
Compound 3 was prepared in a similar manner as described in Example 9.1, a separation by column chramoatography of the regioisomers was performed after the formation of the pyrazole. 
Spoj 3 je pripremljen na sličan način kao što je to opisano u Primjeru 9.1, odijeljivanje kolonskom kromatografijom regioizomera je provedeno nakon formiranja pirazola.
Use according to claim 1 or 2, characterized in that said 2-((1-methylpropyl)amino)ethanol additive has a chemical purity of more than 90%, preferably more than 95% and more preferred more than 99% in respect to 2-((1-methylpropyl)amino)ethanol. 
Uporaba u skladu s patentnim zahtjevom 1 ili 2, karakterizirana na način da navedeni aditiv 2-((1- metilpropil)amino)etanol ima čistoću veću od 90%, poželjno veću od 95% i poželjnije veću od 99% u odnosu na 2- ((1-metilpropiljaminojetanol.
LDL at a final protein concentration of 0.2 mg/ml was incubated in the presence of 2.5 µM haemin and 5 µM H202. 
LDL pri krajnjoj koncentraciji proteina od 0,2 mg/ml inkubiran je u HR P20090152 T3 prisutnosti 2,5 uM hemina i 5 uM H,O,.
The preventive or therapeutic agent for a proliferative disease according to claim 46, wherein the proliferative disease is a cancer. 
Sredstvo za sprječavanje ili liječenje proliferativne bolesti u skladu s patentnim zahtjevom 45, naznačeno time što proliferativna bolest je rak.
J is a single bond. 
J je jednostruka veza,